International external quality assurance of JAK2 V617F quantification

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Julia Asp, Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. julia.asp@gu.se.
  • ,
  • Vibe Skov, Department of Hematology, Roskilde Hospital, Zealand University Hospital, Sygehusvej 10, DK-4000 Roskilde, Denmark.
  • ,
  • Beatriz Bellosillo, Department of Pathology, Hospital del Mar-Parc de Salut Mar, Barcelona, Spain; Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
  • ,
  • Thomas Kristensen, Department of Pathology, Odense University Hospital, Odense, Denmark
  • ,
  • Eric Lippert, CHU de Brest, Brest, France.
  • ,
  • Frank Dicker, Munich Leukemia Laboratory, Munich, Germany.
  • ,
  • Jiri Schwarz, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • ,
  • Marzena Wojtaszewska, Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
  • ,
  • Lars Palmqvist, University of Gothenburg
  • ,
  • Susanna Akiki, Department of Laboratory Medicine and Pathology, Qatar Rehabilitation Institute (QRI), Hamad Bin Khalifa Medical City (HBKM), Doha, Qatar.
  • ,
  • Anni Aggerholm
  • Morten Tolstrup Andersen, Rigshospitalet, Copenhagen, Denmark.
  • ,
  • François Girodon, CHU Dijon/INSERM U866, Dijon, France.
  • ,
  • Lasse Kjær, Department of Hematology, Roskilde Hospital, Zealand University Hospital, Sygehusvej 10, DK-4000 Roskilde, Denmark.
  • ,
  • Elisabeth Oppliger Leibundgut, Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; and.
  • ,
  • Alessandro Pancrazzi, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), Florence, Italy.
  • ,
  • Marta Vorland, Haukeland University Hospital, Bergen, Norway.
  • ,
  • Hajnalka Andrikovics, Central Hospital of Southern Pest, Budapest, Hungary.
  • ,
  • Robert Kralovics, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria, and Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
  • ,
  • Bruno Cassinat, Service de Biologie Cellulaire, AP-HP, Hopital Saint-Louis, Paris, France.
  • ,
  • Margarida Coucelo, Clinical Hematology Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
  • ,
  • Aleksandar Eftimov, Center for Biomolecular Pharmaceutical Analyses, Faculty of Pharmacy, UKiM, Skopje, Republic of Macedonia.
  • ,
  • Karl Haslam, Cancer Trials Ireland and St. James's Hospital, Dublin, Ireland.
  • ,
  • Rajko Kusec, Dubrava University Hospital and Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia.
  • ,
  • Dorota Link-Lenczowska, Molecular Diagnostics Laboratory, Hematology Diagnostics Department, Jagiellonian University Hospital, Krakow, Poland.
  • ,
  • Laurence Lodé, Hématologie Biologique, CHRU de Montpellier, Montpellier, France.
  • ,
  • Karolina Matiakowska, Faculty of Medicine, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
  • ,
  • Dina Naguib, CHU Côte de Nacre, Caen, France.
  • ,
  • Filippo Navaglia, 8 Department of Laboratory Medicine, University Hospital Padova, Padova, Italy.
  • ,
  • Guy Wayne Novotny, Department of Hematology and Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730, Herlev, Denmark.
  • ,
  • Melanie J Percy, Northern Ireland Regional Genetics Centre, Belfast City Hospital, Belfast, United Kingdom.
  • ,
  • Andrey Sudarikov, National Research Center for Hematology, Moscow, Russia.
  • ,
  • Sylvie Hermouet, CRCINA, Inserm UMR892 / CNRS UMR6299, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, Université de Nantes, Nantes, France.
  • ,
  • Niels Pallisgaard, Department of Hematology, Roskilde Hospital, Zealand University Hospital, Sygehusvej 10, DK-4000 Roskilde, Denmark.

External quality assurance (EQA) programs are vital to ensure high quality and standardized results in molecular diagnostics. It is important that EQA for quantitative analysis takes into account the variation in methodology. Results cannot be expected to be more accurate than limits of the technology used, and it is essential to recognize factors causing substantial outlier results. The present study aimed to identify parameters of specific importance for JAK2 V617F quantification by quantitative PCR, using different starting materials, assays, and technical platforms. Sixteen samples were issued to participating laboratories in two EQA rounds. In the first round, 19 laboratories from 11 European countries analyzing JAK2 V617F as part of their routine diagnostics returned results from in-house assays. In the second round, 25 laboratories from 17 countries participated. Despite variations in starting material, assay set-up and instrumentation the laboratories were generally well aligned in the EQA program. However, EQA based on a single technology appears to be a valuable tool to achieve standardization of the quantification of JAK2 V617F allelic burden.

OriginalsprogEngelsk
TidsskriftAnnals of Hematology
Vol/bind98
Nummer5
Sider (fra-til)1111-1118
Antal sider8
ISSN0939-5555
DOI
StatusUdgivet - 2019

Se relationer på Aarhus Universitet Citationsformater

ID: 138778416